GSK Loses Bid to Keep Experts Out of Upcoming Zantac Trial

A California judge on Thursday denied GSK's bid to keep expert testimony linking its discontinued heartburn drug Zantac to cancer out of an upcoming trial, a setback for the British drugmaker.

Related Keywords

Bengaluru ,Karnataka ,India ,London ,City Of ,United Kingdom ,New York ,United States ,Alameda County ,California ,British ,Jose Koilparambil ,Evelio Grillo ,Susan Fenton ,Maggie Fick ,Brendan Pierson ,James Goetz ,Jennifer Moore ,Barclays ,Alameda County Superior Court ,Reuters ,Boehringer Ingelheim ,Pfizer ,Aby Jose Koilparambil ,Bill Berkrot ,Gastroesophageal Reflux Disease Gerd Acid Gastro Oesophageal ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Bladder Cancer ,Alignant Bladder Neoplasm ,Legal Liability ,Patient Safety ,Heartburn ,Carcinogen ,